Syndax Pharmaceuticalsincis A Biopharmaceutical Company Based In New Yorkfocused On Developing Innovative Cancer Therapiesfounded In 2005The Company Aims To Improve The Lives Of Cancer Patients Through Advanced Drug Development And Collaboration With Experts In The Field Syndax S Product Pipeline Includes Revuforjrevumenib A Menin Inhibitor For Treating Relapsed Or Refractory Acute Leukemiaand Niktimvoaxatilimab Csfr An Antibody For Chronic Graft Versus Host Diseasethe Company Is Also Working On Entinostata Class 1 Hdac Inhibitorin Partnership With Eddingpharm International Company Limitedsyndax Collaborates With Various Academic Institutions And Research Organizations To Enhance Its Drug Development Initiativeswith A Dedicated Leadership Team And Approximately 270 Employeessyndax Pharmaceuticals Is Committed To Setting New Standards In Oncology Through Teamwork And Scientific Advancementthe Company Is Publicly Traded On The Nasdaq Under The Ticker Symbol Sndx
